Drug-Eluting Balloons

This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab

October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit ...

Home October 18, 2020
Home
News | Drug-Eluting Balloons

October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the ...

Home October 18, 2020
Home
Videos | Drug-Eluting Balloons

Juan F. Granada, M.D., CEO of the Cardiovascular Research Foundation (CRF) worked on preclinical development work for a ...

Home September 09, 2020
Home
The Philips Healthcare Stellarex drug-coated balloon (DCB). It is cleared for use in peripheral vessels and treatment of failing AV access.
Feature | Drug-Eluting Balloons | Dave Fornell, Editor

Drug-coated balloons (DCB), also referred to as drug-eluting balloons (DEB), were created as a way to reduce very high ...

Home August 06, 2020
Home
News | Drug-Eluting Balloons

July 7, 2020 – MedAlliance announced enrollment of the first patient in its study of Selution SLR 0.014 drug-eluting ...

Home July 07, 2020
Home
Comparison Charts

Drug-coated balloons (DCB), also referred to as drug-eluting balloons, are used to treat peripheral and coronary artery ...

Home
Home
News | Drug-Eluting Balloons

June 19, 2020 — iVascular SLU announced the global launch of Essential Pro, a novel coronary artery drug-coated balloon ...

Home June 19, 2020
Home
News | Drug-Eluting Balloons

June 17, 2020 — MedAlliance announced its second CE mark approval for its Selution SLR 0.014 percutaneous transluminal ...

Home June 18, 2020
Home
News | Drug-Eluting Balloons

May 28, 2020 – MedAlliance has announced the award of its second European CE mark clearance for its Selution SLR 0.014 ...

Home May 28, 2020
Home
News

November 21, 2019 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic In.Pact AV drug-coated balloon ...

Home November 26, 2019
Home
News | Drug-Eluting Balloons

November 7, 2019 — The IN.PACT Arteriovenous (AV) Access randomized trial evaluating the safety and effectiveness of the ...

Home November 14, 2019
Home
News | Drug-Eluting Balloons

November 7, 2019 — Real-world, four-year study results of the In.Pact Admiral drug-coated balloon (DCB) demonstrate long ...

Home November 07, 2019
Home
News | Atherectomy Devices

November 7, 2019 — There was no difference between drug-coated balloons (DCB) vs. plain old balloon angioplasty (POBA) ...

Home November 07, 2019
Home
News | Drug-Eluting Balloons

November 6, 2019 – Positive, two-year data from the first-in-human study of Selution SLR, MedAlliance’s novel sirolimus ...

Home November 06, 2019
Home
News | Peripheral Artery Disease (PAD)

November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-eluting ...

Home November 06, 2019
Home
Subscribe Now